<article id="aarts_2010_p" class="slide" data-ag-slide-name="Aarts 2010 (P)">
    <div class="basic">
      <h1 data-ag-editable="Aarts 2010 (P) Main Title" id="aarts_2010_p_header">Using Neulasta<sup>速</sup> from the first cycle and throughout all cycles can significantly reduce FN in the majority of patients<sup>1</sup></h1>
      <div id="ne_page2_data_top_p" class="red_subtitle2" data-ag-editable="Aarts 2010 (P) Top Copy"><p>Neulasta<sup>速</sup> protection throughout all cycles compared with the first two cycles only is associated with a significantly lower risk of FN<sup>1</sup></p></div>
      <div id="ne_page2_graph1_p" class="main_content_style">
         <img src="content/images/pragmatist_pages/neulasta_efficacy/ne_page2_graph1_bg.png" width="425" height="310" data-ag-editable="Aarts 2010 (P) Graph Background" />
          <div id="aarts_2010_p_graph_content"  data-ag-editable="Aarts 2010 (P) Graph Content">
              <p id="graph_vertical_axis_title">Observed FN rates (% of patients)</p>
              <p id="graph_column1_title">Neulasta<sup>速</sup> cycle 1 and 2 only</p>
              <p id="graph_column2_title">Neulasta<sup>速</sup> all cycles</p>
              <p id="graph_bottom_text">Adapted from Aarts M <span class="et_al">et al.</span> Supp Care Cancer 2010; 18(Suppl 3); S115-116</p>
          </div>
         <div id="ne_page2_graph1_p_arrow1">
            <img src="content/images/pragmatist_pages/neulasta_efficacy/ne_page2_graph1_arrow1.png" width="131" height="168" data-ag-editable="Aarts 2010 (P) Graph Left Bar" />
             <p class="aarts_2010_p_graph_values" id="graph_value_1">26.8</p>
         </div>
         <div id="ne_page2_graph1_p_arrow2">
            <img src="content/images/pragmatist_pages/neulasta_efficacy/ne_page2_graph1_arrow2.png" width="131" height="140" data-ag-editable="Aarts 2010 (P) Graph Right Bar" />
             <p class="aarts_2010_p_graph_values" id="graph_value_2">p &lt; 0.0001</p>
         </div>
         <div id="ne_page2_graph1_p_arrow3">
            <img src="content/images/pragmatist_pages/neulasta_efficacy/ne_page2_graph1_arrow3.png" width="131" height="23" data-ag-editable="Aarts 2010 (P) Graph Right Arrow" />
             <p class="aarts_2010_p_graph_values" id="graph_value_3">3.8</p>
         </div>
      </div>
      <div id="ne_page2_data_bottom_p" data-ag-editable="Aarts 2010 (P) Bottom Copy" class="red_subtitle2">The study was stopped early after a planned interim analysis based on the unfavourable differences in incidence of FN<sup>1</sup></div>
    </div>
    <!-- Reference Information Starts -->
    
    <div class="lightbox_data" id="aarts_2010_p_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Aarts 2010 (P) References Title">References:</strong></p>
          <div data-ag-editable="Aarts 2010 (P) References List">
             <ol>
                <li>Aarts M <em>et al.</em> Primary G-CSF Prophylaxis During The First Two Cycles Only Or Throughout All Chemotherapy Cycles In Breast Cancer Patients At Risk Of Febrile Neutropenia: First Results From A Phase III Trial Of The Dutch Breast Cancer Trialists Group (Boog). Supp Care Cancer 2010; 18(Suppl 3):S115-116</li>       
             </ol>
          </div>
          <p data-ag-editable="Aarts 2010 (P) References Bottom Copy">Breast cancer patients (n=162) with an increased risk of FN (&gt;20%) were randomised 1:1 to primary G-CSF prophylaxis during the first two chemotherapy cycles only, or to G-CSF prophylaxis throughout all cycles.</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
    
</article>